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Epidemiological and Genetic 
Considerations in Retinoblastoma
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Abstract
Retinoblastoma (Rb) is the most common primary intraocular malignancy of 
childhood. The incidence of Rb is stable worldwide at one case per 16,000–18,000 
live births. It is estimated that 7800–8800 Rb cases were newly diagnosed globally 
in 2017. Over 80% of these are in low- and middle-income countries (LMICs) in 
Asia and Africa. So far, there is no validated evidence that retinoblastoma incidence 
is associated with gender, ethnicity or geographical factors. A link between human 
papillomavirus (HPV) and Rb is being investigated to establish its role in the patho-
physiology of the sporadic form of the disease. Survival rates for Rb vary greatly 
between countries: while almost all Rb cases from high-income countries survive, 
cases in LMICs have a mortality rate of up to 70%.
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1. Introduction
Retinoblastoma (Rb) is the most common intraocular malignancy of childhood, 
but a relatively rare disease, occurring in approximately 1: 16,000–18,000 live 
births [1]. Its incidence is uniform across populations, with no known gender, racial 
or ethnic predilection. Rb develops in early childhood, with the vast majority of 
cases that present before the age of 5 years. The disease can involve one or both eyes 
and can be inherited from an affected parent or developed de novo in a child with 
no family history of Rb. This chapter discusses the epidemiological aspects of Rb, 
including basic concepts in Rb development, incidence and prevalence, age, sex and 
racial considerations, associated environmental factors, trilateral Rb and secondary 
non-Rb malignancies.
2. Genetic considerations
Rb can be inherited by an affected parent or developed de novo in a child with no 
known family history of Rb (i.e., sporadic). The neoplasm can involve one or both 
eyes and may present in an asymmetrical manner, with different grades in each eye 
at presentation or even initially appearing as unilateral and becoming bilateral in the 
course of the disease. The disorder, which is believed to originate from an immature 
cone photoreceptor cell early in childhood, is initiated in most cases by a mutation in 
the RB1 gene. RB1 loss initially produces a retinoma, the benign precursor of Rb, and 
causes genomic instability that subsequently leads to the cancerous tumor, Rb.
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In hereditary Rb cases, a single RB1 allele is mutated in most or every cell of a 
child’s body. An additional “hit” in the second allele in the retina will result in clini-
cal Rb. These cases usually present with bilateral and multifocal disease at a median 
age of 15 months, but can present also in unilateral disease, albeit less frequently. 
Between 30 and 37% of Rb cases are bilateral [2], and all bilateral cases are heredi-
tary. However, it is estimated that up to 18% of unilateral cases are also hereditary 
[3]. This emphasizes the importance of genetic testing in addition to clinical 
examination, as it has direct impact on the recommended screening frequency of 
the fellow eye and occasionally on management decisions.
Non-hereditary cases (i.e., somatic) usually present at a later age (median: 
24 months) with unilateral unifocal disease. In order for the disease to develop in 
this scenario, two consecutive “hits” occur in a retinal cell, resulting in both RB1 
alleles mutated and the development of clinical Rb.
All familial cases are hereditary, but not necessarily vice versa. A mutation 
can occur at or after conception in an individual with no family history of Rb, 
and depending on the stage at which it occurs, some of the fetus’ cells will have 
a mutated RB1 allele, resulting in mosaicism. Children with mosaicism are at 
increased risk of developing Rb. The disease in this scenario is not inherited, hence 
siblings of the proband are not at risk, but offspring potentially are, and therefore 
should be screened soon after birth.
Hereditary Rb has been associated with an increased risk of developing second-
ary non-Rb malignancies [4, 5], including sarcomas, carcinomas, malignant mela-
noma, and neuroectodermal cancers. Secondary tumors were reported to occur in 
up to 20% of cases in 10 years and the incidence was reported to directly correlate 
with the time lag from initial diagnosis. It is also well established that treatment by 
radiotherapy increases the risk of developing secondary tumors, both in and outside 
the field of radiation [6]. Draper et al. showed in a series of nearly 400 hereditary 
cases that close to 10% developed secondary malignancies, mainly osteosarcomas, 
most of which were in the field of radiation [6].
Trilateral Rb is a syndrome consisting of unilateral or bilateral hereditary Rb 
associated with an intracranial neuroblastic tumor that develops most often in the 
pineal gland (i.e., Pinealblastoma). On a meta-analysis by Kivelä [7], 2% of trilat-
eral Rb cases had a brain tumor but no intraocular Rb, 12% had unilateral Rb and 
the remaining had bilateral disease.
3. Magnitude and distribution of Rb
3.1 Global incidence and prevalence
The reported incidence of Rb is constant worldwide at one case per 16,000–
18,000 live births [8, 9]. In 2009 the estimated global annual incidence of Rb ranged 
from 7200 to 8100 children. The global birth rate has dropped since then, from 20.3 
to 18.6 births per 1000 population, but the world’s population has grown from 6593 
to 7550 million [10], resulting in an estimated 7800–8800 newly diagnosed Rb cases 
globally in 2017. The highest disease prevalence is recorded in areas with high birth 
rates, which is the case of many low- and middle-income countries (LMICs).
3.2 Global distribution and survival
Over 80% of the newly diagnosed cases are in LMICs in Asia and Africa (Table 1 
and Figure 1) [3]. These regions also show the lowest survival rate, reporting up to 
70% mortality from Rb. Only about 15% of children with Rb reside in high-income 
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countries, and their prognosis is considered to be very good, with an estimated 
disease-free survival rate of nearly 100% [11].
4. Rb determinants
4.1 Age
According to the World Health Organization’s compendium of data from 
cancer registries, the average Rb incidence rate in children aged 0–4 years is >10 
High incidence 
(1:16,000)
Low incidence 
(1:18,000)
Average 
incidence
n n n (%)
Continent
North America 273 242 258 (3.1)
Latin America and the Caribbean 669 595 632 (7.7)
Africa 2567 2282 2425 (29.5)
Asia 4656 4139 4398 (53.5)
Europe 504 448 476 (5.8)
Oceania 37 32 35 (0.4)
National income level
Low 1413 1256 1335 (16.2)
Lower-middle 4221 3752 3987 (48.5)
Upper-middle 2272 2020 2146 (26.1)
High 800 711 756 (9.2)
Table 1. 
Estimated number of newly diagnosed retinoblastoma patients in 2017.
Figure 1. 
Estimated average number of newly diagnosed Rb patients in 2017 by national income level. Income level data 
source: United Nations, Department of Economic and Social Affairs PD [10].
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per million compared to <1 per million in children aged 5–9 years, and significantly 
lower beyond that age [12].
It is difficult to accurately estimate the time at which Rb tumors first develop as 
information about the biological development of the disease is essentially lacking. 
There are three important time points associated with Rb development and the time 
of Rb diagnosis. These include (1) retinal tumor growth following two RB1 mutative 
events, (2) parents/guardians noticing the first ocular sign, and (3) presentation to 
an Rb center, at which diagnosis is made and treatment given.
As discussed earlier, the median age of presentation for bilateral cases is 
15 months, while for non-hereditary cases is 24 months. Most of the available 
knowledge originates from familial cases in high income countries, where Rb 
centers commonly perform screening tests for patients at risk (i.e., siblings of 
probands). Screening allows detection of small tumors very early in the course of 
disease, relatively soon after they develop. However, since sporadic cases are not 
screened, we rely only on age of presentation at two time points. First, the time 
at which the parents/guardians notice an ocular abnormality, it is usually a white 
pupillary reflex (i.e., leukocoria). Second, the time at which the final diagnosis is 
made, which is dependent on the time it takes the patient to reach the Rb center in 
the referral pathway.
The body of knowledge on Rb is based on retrospective studies, hence, the most 
accurate data in this context reports the age of the child’s first presentation at an Rb 
center. Nevertheless, several studies have investigated the lag time from the first 
ocular sign as noticed by parents, to the presenting sign at the Rb center. In this 
respect, a huge gap exists between high-income countries and LMICs. In the UK, 
the referral time from sign onset to visiting primary care was found to be 28 days, 
primary care to ophthalmologist 3 days, and the time from local ophthalmologist 
to an Rb Unit was 6 days. In low-income countries, these time lags are considerably 
longer, and can take 6 months or more [13].
Rarely, Rb can develop in adults older than 20 years of age, with fewer than 50 
case reports found in the literature. Adult-onset Rb is quite different in its presenta-
tion compared to its pediatric form, and due to its rarity, it is usually not considered 
in the differential diagnosis, often leading to delay in diagnosis.
In trilateral Rb [7], rates of familial Rb, the age at diagnosis and laterality were 
found to be similar to ordinary hereditary Rb. Cases of suprasellar trilateral Rb, 
however, were diagnosed at an earlier age as compared to Pinealblastoma. The 
median age of Rb diagnosis was 5 months, and cases of familial Rb were diagnosed 
at an earlier age than non-familial cases.
4.2 Gender
There is no known gender predilection in Rb, and although this notion is widely 
quoted in many scientific reports in the field, it has not actually been thoroughly 
investigated. Based on data available from the Surveillance, Epidemiology, and End 
Results (SEER) program of the National Cancer Institute, Tamboli et al. calculated 
the incidence of Rb in the United States from 1974 to 1985 and found no gender dif-
ferences [14]. Gurney et al. used the same data source for similar years (1974–1989), 
but concluded that rates of Rb were higher in females [15], and Wong et al., in 
contrast, found an excess of Rb cases in males using the SEER database for the 
years 2000–2009 [8]. RB1 gene is located on chromosome 13 and there is no known 
relation to any of the sex chromosomes. There is also no evidence of an associa-
tion between sex hormones and Rb. Cases of trilateral Rb do not show any gender 
predilection either [7].
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4.3 Race
Similar to sex, there is no known association between race and Rb, although 
some exceptions have been reported. Gurney et al. found higher rates of Rb in 
blacks as compared to whites in the United States [15]. Broaddus et al., in contrast, 
found that the overall mean age-adjusted incidence of Rb was 11.3 for Caucasians 
and 13.0 for blacks, with no significant difference between the two populations [8]. 
Krishna et al. examined the incidence of Rb using data from the International 
Agency for Research on Cancer [16], and found no significant difference between 
white populations in the United States and Europe/Australia, Hispanic popula-
tions in Spain and the United States, and Hispanic populations in Uruguay and 
the United States. They concluded that Rb incidence is similar among varied 
populations.
4.4 Environmental factors
Several studies have shown a link between human papillomavirus (HPV) and 
the development of sporadic Rb [17, 18]. Shetty et al. analyzed enucleated eyes 
with Rb and found that 70% were positive for HPV [17], suggesting that the virus 
may play a role in the development of sporadic RB. Anand et al. tested the presence 
of HPV in Rb tissue (formalin-fixed paraffin-embedded tissue and fresh-frozen 
specimens) and found that nearly a quarter of the specimens were positive for HPV 
[19]. However, the implications of the presence of HPV in Rb tissue and its role in 
carcinogenesis warrant further study. Jemal et al. investigated the relation between 
Rb incidence and ultraviolet (UV-B) radiation levels in the SEER program and 
found no statistically significant correlations [20]. To the best of our knowledge, 
there are no other reports focused on any additional environmental factors in 
association with Rb development.
5. Conclusions
Rb is the most common primary intraocular malignancy of childhood. The 
disease can involve one or both eyes and can be inherited or sporadic. The incidence 
of Rb is stable worldwide at one case per 16,000–18,000 live births. The average Rb 
incidence rate in children aged 0–4 years is >10 per million compared to <1 per mil-
lion in children aged 5–9 years, and significantly lower beyond that age. In 2017, 
globally, an estimated 7800–8800 Rb cases were newly diagnosed. Over 80% of 
these are in LMICs in Asia and Africa.
So far, there is no validated evidence that retinoblastoma incidence is associated 
with gender, ethnicity or geographical factors. Studies have shown the presence 
of HPV in sporadic Rb tissue. Its role in carcinogenesis and the development of 
sporadic Rb warrants further investigation.
We lack accurate information about the biological development of Rb which cre-
ates difficulties in estimating the time at which Rb tumors first develop. In familial 
cases from high-income countries, genetic screening is routinely conducted. 
However, in low-income countries this is not the case, and in all settings sporadic 
cases are not screened. In these cases, we rely on time of presentation, which is 
strongly influenced by the referral pathways in different settings.
Survival rates are related to the time taken for the child to present at an Rb center 
and vary greatly between countries: while almost all Rb cases from high-income 
countries survive, cases in LMICs have a mortality rate of 70%.
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